Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7.
Kovalová M, Havlíček L, Djukic S, Škerlová J, Peřina M, Pospíšil T, Řezníčková E, Řezáčová P, Jorda R, Kryštof V. Kovalová M, et al. Among authors: havlicek l. Biomed Pharmacother. 2023 May;161:114492. doi: 10.1016/j.biopha.2023.114492. Epub 2023 Mar 15. Biomed Pharmacother. 2023. PMID: 36931035 Free article.
Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
Řezníčková E, Weitensteiner S, Havlíček L, Jorda R, Gucký T, Berka K, Bazgier V, Zahler S, Kryštof V, Strnad M. Řezníčková E, et al. Among authors: havlicek l. Chem Biol Drug Des. 2015 Dec;86(6):1528-40. doi: 10.1111/cbdd.12618. Epub 2015 Sep 16. Chem Biol Drug Des. 2015. PMID: 26198005
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Vymětalová L, Havlíček L, Šturc A, Skrášková Z, Jorda R, Pospíšil T, Strnad M, Kryštof V. Vymětalová L, et al. Among authors: havlicek l. Eur J Med Chem. 2016 Mar 3;110:291-301. doi: 10.1016/j.ejmech.2016.01.011. Epub 2016 Jan 18. Eur J Med Chem. 2016. PMID: 26851505
3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
Jorda R, Havlíček L, Šturc A, Tušková D, Daumová L, Alam M, Škerlová J, Nekardová M, Peřina M, Pospíšil T, Široká J, Urbánek L, Pachl P, Řezáčová P, Strnad M, Klener P, Kryštof V. Jorda R, et al. Among authors: havlicek l. J Med Chem. 2019 May 9;62(9):4606-4623. doi: 10.1021/acs.jmedchem.9b00189. Epub 2019 Apr 17. J Med Chem. 2019. PMID: 30943029
Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines.
Jorda R, Sacerdoti-Sierra N, Voller J, Havlíček L, Kráčalíková K, Nowicki MW, Nasereddin A, Kryštof V, Strnad M, Walkinshaw MD, Jaffe CL. Jorda R, et al. Among authors: havlicek l. Bioorg Med Chem Lett. 2011 Jul 15;21(14):4233-7. doi: 10.1016/j.bmcl.2011.05.076. Epub 2011 May 27. Bioorg Med Chem Lett. 2011. PMID: 21683592
2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro.
Řezníčková E, Popa A, Gucký T, Zatloukal M, Havlíček L, Bazgier V, Berka K, Jorda R, Popa I, Nasereddin A, Jaffe CL, Kryštof V, Strnad M. Řezníčková E, et al. Among authors: havlicek l. Bioorg Med Chem Lett. 2015 Jun 1;25(11):2298-301. doi: 10.1016/j.bmcl.2015.04.030. Epub 2015 Apr 16. Bioorg Med Chem Lett. 2015. PMID: 25937014
50 results